We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

70 hedge funds and large institutions have $241M invested in Intellia Therapeutics in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

51.07% more ownership

Funds ownership: 0% → 51.07% (+51%)

8% more funds holding

Funds holding: 65 → 70 (+5)

1% less capital invested

Capital invested by funds: $242M → $241M (-$1.43M)

Holders
70
Holders Change
+5
Holders Change %
+7.69%
% of All Funds
1.75%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
13
Increased
24
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$7.93M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.48M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.58M
4
Norges Bank
Norges Bank
Norway
+$1.02M
5
AG
Artal Group
Luxembourg
+$676K

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$9.22M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.5M
3
EC
EcoR1 Capital
California
-$3.42M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$2.32M
5
Invesco
Invesco
Georgia
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
26
ARK Investment Management
Florida
$348K +$399K +26,544 New
BIM
27
BlackRock Investment Management
Delaware
$339K – – –
AllianceBernstein
28
AllianceBernstein
Tennessee
$338K +$43.6K +2,900 +13%
Charles Schwab
29
Charles Schwab
California
$333K +$20.8K +1,386 +6%
TCIM
30
TIAA CREF Investment Management
New York
$333K +$69.2K +4,606 +22%
ProShare Advisors
31
ProShare Advisors
Maryland
$326K +$374K +24,902 New
Swiss National Bank
32
Swiss National Bank
Switzerland
$271K +$311K +20,700 New
VKH
33
Virtu KCG Holdings
New York
$269K +$309K +20,545 New
PA
34
Perceptive Advisors
New York
$192K – – –
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$188K -$6.01K -400 -3%
CS
36
Credit Suisse
Switzerland
$162K -$31K -2,061 -14%
UBS Group
37
UBS Group
Switzerland
$150K +$151K +10,038 +708%
Barclays
38
Barclays
United Kingdom
$148K +$167K +11,145 +16,390%
TA
39
Teachers Advisors
New York
$144K – – –
Commonwealth Equity Services
40
Commonwealth Equity Services
Massachusetts
$142K +$162K +10,800 New
CAM
41
ClariVest Asset Management
California
$119K -$4.01K -267 -3%
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$117K +$13.2K +881 +11%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$94K – – –
NFA
44
Nationwide Fund Advisors
Ohio
$60K – – –
Deutsche Bank
45
Deutsche Bank
Germany
$57K +$24.3K +1,617 +57%
AIG
46
American International Group
New York
$53K -$180 -12 -0.3%
WCM
47
Wildcat Capital Management
New York
$46K +$53.2K +3,542 New
Bank of America
48
Bank of America
North Carolina
$43K +$39.5K +2,632 +405%
Wells Fargo
49
Wells Fargo
California
$42K +$13.5K +900 +38%
SO
50
STRS Ohio
Ohio
$41K – – –
1
2
3 4

NTLA Hedge Fund Activity: Q4 2016 in Review

70 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2016, worth a combined $241M — down 0.59% from $242M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new NTLA positions and 7 closed out — a net gain of 6 holders — while 24 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $7.93M. The largest seller was BlackRock Advisors, cutting an estimated $9.22M.

  • 70 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2016, up from 65 in Q3 2016.
  • Funds reported $241M of Intellia Therapeutics stock for Q4 2016, down 0.59% quarter-over-quarter.
  • 13 funds opened new Intellia Therapeutics positions in Q4 2016 and 7 closed out, a net change of +6 holders.
  • The largest Intellia Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $7.93M added.
  • The largest Intellia Therapeutics seller in Q4 2016 was BlackRock Advisors, an estimated $9.22M sold.

Based on aggregated 13F filings for Q4 2016.